Insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Neurocrine Biosciences Inc (NBIX) since 2015 are shown in Table 1 and Table 2. Table 1 shows the monthly insider trading data of Neurocrine Biosciences Inc. (See page 1 of this report.) Table 2 shows the detailed insider transactions. This company's CIK number is 914475.
Total stock buying since 2015: $0.
Total stock sales since 2015: $553,389,273.
Total stock option exercises since 2015: $112,361,564.
| Insider Buying | Insider Sales | Option Exercises | ||||
|---|---|---|---|---|---|---|
| Year | Shares | Value | Shares | Value | Shares | Value |
| 2025 | 0 | $0 | 381,272 | $52,092,153 | 413,767 | $15,477,653 |
| 2024 | 0 | $0 | 767,118 | $104,902,106 | 734,237 | $33,104,501 |
| 2023 | 0 | $0 | 602,981 | $67,979,111 | 314,830 | $12,705,238 |
| 2022 | 0 | $0 | 339,724 | $35,585,341 | 275,903 | $8,378,407 |
| 2021 | 0 | $0 | 470,442 | $52,030,343 | 373,591 | $5,060,074 |
| 2020 | 0 | $0 | 352,778 | $38,556,859 | 168,347 | $8,930,685 |
| 2019 | 0 | $0 | 506,699 | $45,323,842 | 438,362 | $9,802,547 |
| 2018 | 0 | $0 | 801,747 | $73,265,316 | 852,782 | $10,193,425 |
| 2017 | 0 | $0 | 675,618 | $38,755,247 | 649,073 | $4,790,919 |
| 2016 | 0 | $0 | 204,895 | $9,503,074 | 139,870 | $648,814 |
| 2015 | 0 | $0 | 868,262 | $35,395,881 | 715,887 | $3,269,301 |
| Trade Date | Insider Name | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2024-02-28 | Delaet Ingrid (Chief Regulatory Officer) | Option Ex | 6,544 | 79.02 | 517,106 |
| 2024-02-28 | Benevich Eric (Chief Commercial Officer) | Sale | 75,000 | 134.69 | 10,101,600 |
| 2024-02-28 | Benevich Eric (Chief Commercial Officer) | Option Ex | 75,000 | 61.13 | 4,584,750 |
| 2024-02-27 | Norwalk Leslie V (Director) | Sale | 8,000 | 135.67 | 1,085,392 |
| 2024-02-27 | Norwalk Leslie V (Director) | Option Ex | 8,000 | 84.95 | 679,600 |
| 2024-02-20 | Pops Richard F (Director) | Sale | 15,000 | 132.47 | 1,987,050 |
| 2024-02-20 | Pops Richard F (Director) | Option Ex | 15,000 | 12.98 | 194,700 |
| 2024-02-13 | Delaet Ingrid (Chief Regulatory Officer) | Sale | 716 | 133.03 | 95,253 |
| 2024-02-13 | Boyer David W. (Chief Corp. Affairs Officer) | Sale | 1,811 | 133.07 | 240,993 |
| 2024-02-13 | Onyia Jude (Chief Scientific Officer) | Sale | 1,432 | 132.94 | 190,371 |
| 2024-02-13 | Roberts Eiry (Chief Medical Officer) | Sale | 1,114 | 132.96 | 148,121 |
| 2024-02-13 | Abernethy Matt (Chief Financial Officer) | Sale | 1,352 | 132.85 | 179,611 |
| 2024-02-13 | Benevich Eric (Chief Commercial Officer) | Sale | 1,098 | 133.01 | 146,050 |
| 2024-02-13 | Gano Kyle (Chief Business Development Officer) | Sale | 1,352 | 132.90 | 179,674 |
| 2024-02-13 | Lippoldt Darin (Chief Legal Officer) | Sale | 1,098 | 133.00 | 146,028 |
| 2024-02-13 | Gorman Kevin Charles (Chief Executive Officer) | Sale | 2,832 | 133.02 | 376,701 |
| 2024-02-13 | Gorman Kevin Charles (Chief Executive Officer) | Option Ex | 5,090 | 39.62 | 201,640 |
| 2024-02-08 | Boyer David W. (Chief Corp. Affairs Officer) | Sale | 1,328 | 135.49 | 179,924 |
| 2024-02-08 | Cooke Julie (Chief Human Resources Officer) | Sale | 1,329 | 135.50 | 180,086 |
| 2024-02-08 | Roberts Eiry (Chief Medical Officer) | Sale | 980 | 134.21 | 131,521 |
| 2024-02-08 | Abernethy Matt (Chief Financial Officer) | Sale | 980 | 134.21 | 131,529 |
| 2024-02-08 | Benevich Eric (Chief Commercial Officer) | Sale | 980 | 134.19 | 131,509 |
| 2024-02-08 | Gano Kyle (Chief Business Development Officer) | Sale | 980 | 134.20 | 131,518 |
| 2024-02-08 | Lippoldt Darin (Chief Legal Officer) | Sale | 911 | 134.24 | 122,288 |
| 2024-02-08 | Gorman Kevin Charles (Chief Executive Officer) | Sale | 2,274 | 134.15 | 305,052 |
| 2024-02-06 | Boyer David W. (Chief Corp. Affairs Officer) | Sale | 456 | 141.96 | 64,733 |
| 2024-02-06 | Cooke Julie (Chief Human Resources Officer) | Sale | 1,215 | 142.07 | 172,610 |
| 2024-02-06 | Roberts Eiry (Chief Medical Officer) | Sale | 1,121 | 142.24 | 159,446 |
| 2024-02-06 | Abernethy Matt (Chief Financial Officer) | Sale | 1,280 | 142.19 | 182,000 |
| 2024-02-06 | Benevich Eric (Chief Commercial Officer) | Sale | 1,280 | 142.12 | 181,909 |
| 2024-02-06 | Gano Kyle (Chief Business Development Officer) | Sale | 1,600 | 142.20 | 227,521 |
| 2024-02-06 | Lippoldt Darin (Chief Legal Officer) | Sale | 1,041 | 142.17 | 147,994 |
| 2024-02-06 | Gorman Kevin Charles (Chief Executive Officer) | Sale | 3,040 | 142.18 | 432,218 |
| 2024-02-01 | Delaet Ingrid (Chief Regulatory Officer) | Sale | 623 | 139.77 | 87,076 |
| 2024-01-31 | Delaet Ingrid (Chief Regulatory Officer) | Sale | 422 | 141.94 | 59,898 |
| 2024-01-31 | Boyer David W. (Chief Corp. Affairs Officer) | Sale | 2,096 | 140.79 | 295,106 |
| 2024-01-31 | Onyia Jude (Chief Scientific Officer) | Sale | 126 | 141.94 | 17,884 |
| 2024-01-31 | Cooke Julie (Chief Human Resources Officer) | Sale | 1,740 | 141.32 | 245,898 |
| 2024-01-31 | Roberts Eiry (Chief Medical Officer) | Sale | 1,457 | 140.79 | 205,132 |
| 2024-01-31 | Abernethy Matt (Chief Financial Officer) | Sale | 1,283 | 140.72 | 180,538 |
| 2024-01-31 | Benevich Eric (Chief Commercial Officer) | Sale | 1,207 | 140.78 | 169,926 |
| 2024-01-31 | Gano Kyle (Chief Business Development Officer) | Sale | 1,541 | 140.70 | 216,812 |
| 2024-01-31 | Lippoldt Darin (Chief Legal Officer) | Sale | 1,250 | 140.65 | 175,810 |
| 2024-01-31 | Gorman Kevin Charles (Chief Executive Officer) | Sale | 2,707 | 140.69 | 380,845 |
| 2024-01-22 | Lippoldt Darin (Chief Legal Officer) | Sale | 10,000 | 139.85 | 1,398,550 |
| 2024-01-22 | Lippoldt Darin (Chief Legal Officer) | Option Ex | 10,000 | 79.02 | 790,200 |
| 2024-01-09 | Gorman Kevin Charles (Chief Executive Officer) | Sale | 62,023 | 134.01 | 8,311,888 |
| 2024-01-09 | Gorman Kevin Charles (Chief Executive Officer) | Option Ex | 62,023 | 19.59 | 1,215,030 |
| 2024-01-08 | Gorman Kevin Charles (Chief Executive Officer) | Sale | 105,835 | 132.44 | 14,016,575 |
| 2024-01-08 | Gorman Kevin Charles (Chief Executive Officer) | Option Ex | 105,835 | 19.59 | 2,073,307 |
| 2024-01-02 | Gano Kyle (Chief Business Development Officer) | Sale | 75,000 | 131.46 | 9,859,275 |
| 2024-01-02 | Gano Kyle (Chief Business Development Officer) | Option Ex | 75,000 | 19.59 | 1,469,250 |
| 2024-01-02 | Rastetter William H (Director) | Sale | 11,044 | 131.47 | 1,451,932 |
| 2024-01-02 | Rastetter William H (Director) | Option Ex | 20,000 | 12.98 | 259,600 |
| 2023-12-22 | Cooke Julie (Chief Human Resources Officer) | Sale | 24,000 | 128.39 | 3,081,408 |
| 2023-12-22 | Cooke Julie (Chief Human Resources Officer) | Option Ex | 24,000 | 71.44 | 1,714,440 |
| 2023-12-22 | Roberts Eiry (Chief Medical Officer) | Sale | 10,000 | 126.75 | 1,267,450 |
| 2023-12-22 | Lyons Gary A (Director) | Sale | 10,000 | 130.04 | 1,300,440 |
| 2023-12-12 | Roberts Eiry (Chief Medical Officer) | Sale | 13,925 | 120.31 | 1,675,247 |
| 2023-12-12 | Roberts Eiry (Chief Medical Officer) | Option Ex | 13,925 | 81.05 | 1,128,621 |
| 2023-12-08 | Roberts Eiry (Chief Medical Officer) | Sale | 300 | 120.08 | 36,023 |
| 2023-12-08 | Roberts Eiry (Chief Medical Officer) | Option Ex | 300 | 81.05 | 24,315 |
| 2023-12-07 | Roberts Eiry (Chief Medical Officer) | Sale | 77,379 | 120.37 | 9,314,264 |
| 2023-12-07 | Roberts Eiry (Chief Medical Officer) | Option Ex | 77,379 | 78.92 | 6,106,982 |
| 2023-12-06 | Roberts Eiry (Chief Medical Officer) | Sale | 8,396 | 120.03 | 1,007,780 |
| 2023-12-06 | Roberts Eiry (Chief Medical Officer) | Option Ex | 8,396 | 77.81 | 653,292 |
| 2023-12-06 | Lippoldt Darin (Chief Legal Officer) | Sale | 20,830 | 119.86 | 2,496,642 |
| 2023-12-06 | Lippoldt Darin (Chief Legal Officer) | Option Ex | 20,830 | 43.24 | 900,689 |
| 2023-12-01 | Lyons Gary A (Director) | Sale | 5,000 | 116.77 | 583,835 |
| 2023-12-01 | Lyons Gary A (Director) | Option Ex | 5,000 | 12.98 | 64,900 |
| 2023-11-29 | Onyia Jude (Chief Scientific Officer) | Sale | 2,331 | 113.57 | 264,734 |
| 2023-11-27 | Lippoldt Darin (Chief Legal Officer) | Sale | 10,919 | 112.27 | 1,225,908 |
| 2023-10-02 | Boyer David W. (Chief Corp. Affairs Officer) | Sale | 1,437 | 112.68 | 161,921 |
| 2023-09-12 | Lyons Gary A (Director) | Sale | 5,000 | 115.02 | 575,120 |
| 2023-09-12 | Lyons Gary A (Director) | Option Ex | 5,000 | 12.98 | 64,900 |
| 2023-09-01 | Cooke Julie (Chief Human Resources Officer) | Sale | 824 | 110.93 | 91,406 |
| 2023-09-01 | Lyons Gary A (Director) | Sale | 5,000 | 110.06 | 550,315 |
| 2023-09-01 | Lyons Gary A (Director) | Option Ex | 5,000 | 12.98 | 64,900 |
| 2023-08-30 | Boyer David W. (Chief Corp. Affairs Officer) | Sale | 2,733 | 107.56 | 293,964 |
| 2023-08-28 | Delaet Ingrid (Chief Regulatory Officer) | Sale | 1,431 | 107.52 | 153,861 |
| 2023-08-21 | Delaet Ingrid (Chief Regulatory Officer) | Sale | 1,404 | 107.42 | 150,820 |
| 2023-08-21 | Boyer David W. (Chief Corp. Affairs Officer) | Sale | 1,600 | 107.41 | 171,862 |
| 2023-08-21 | Onyia Jude (Chief Scientific Officer) | Sale | 3,198 | 107.37 | 343,369 |
| 2023-08-21 | Cooke Julie (Chief Human Resources Officer) | Sale | 2,132 | 107.41 | 228,991 |
| 2023-08-21 | Roberts Eiry (Chief Medical Officer) | Sale | 3,198 | 107.38 | 343,388 |
| 2023-08-21 | Abernethy Matt (Chief Financial Officer) | Sale | 2,132 | 107.39 | 228,957 |
| 2023-08-21 | Benevich Eric (Chief Commercial Officer) | Sale | 1,600 | 107.40 | 171,836 |
| 2023-08-21 | Gano Kyle (Chief Business Development Officer) | Sale | 2,132 | 107.41 | 228,993 |
| 2023-08-21 | Lippoldt Darin (Chief Legal Officer) | Sale | 2,132 | 107.39 | 228,951 |
| 2023-08-21 | Gorman Kevin Charles (Chief Executive Officer) | Sale | 9,328 | 107.40 | 1,001,817 |
| 2023-05-01 | Cooke Julie (Chief Human Resources Officer) | Sale | 11,397 | 103.89 | 1,184,045 |
| 2023-05-01 | Rastetter William H (Director) | Sale | 4,300 | 101.43 | 436,136 |
| 2023-05-01 | Rastetter William H (Director) | Option Ex | 7,625 | 12.71 | 96,913 |
| 2023-04-25 | Cooke Julie (Chief Human Resources Officer) | Sale | 100 | 103.82 | 10,382 |
| 2023-04-24 | Roberts Eiry (Chief Medical Officer) | Sale | 14,400 | 103.48 | 1,490,054 |
| 2023-04-21 | Rastetter William H (Director) | Sale | 6,034 | 105.04 | 633,787 |
| 2023-04-21 | Rastetter William H (Director) | Option Ex | 10,765 | 12.71 | 136,823 |
| 2023-04-19 | Rastetter William H (Director) | Sale | 903 | 105.00 | 94,818 |
| 2023-04-19 | Rastetter William H (Director) | Option Ex | 1,610 | 12.71 | 20,463 |
| 2023-02-08 | Boyer David W. (Chief Corp. Affairs Officer) | Sale | 700 | 104.11 | 72,876 |
| 2023-02-08 | Cooke Julie (Chief Human Resources Officer) | Sale | 1,328 | 103.82 | 137,874 |
| 2023-02-08 | Roberts Eiry (Chief Medical Officer) | Sale | 980 | 104.16 | 102,071 |
| 2023-02-08 | Abernethy Matt (Chief Financial Officer) | Sale | 980 | 104.19 | 102,110 |
| 2023-02-08 | Benevich Eric (Chief Commercial Officer) | Sale | 980 | 104.12 | 102,035 |
| 2023-02-08 | Gano Kyle (Chief Business Development Officer) | Sale | 980 | 103.99 | 101,910 |
| 2023-02-08 | Lloyd-smith Malcolm (Chief Integration Officer) | Sale | 701 | 103.83 | 72,784 |
| 2023-02-08 | Lippoldt Darin (Chief Legal Officer) | Sale | 911 | 104.08 | 94,815 |
| 2023-02-08 | Gorman Kevin Charles (Chief Executive Officer) | Sale | 2,274 | 104.30 | 237,185 |
| 2023-02-07 | Boyer David W. (Chief Corp. Affairs Officer) | Sale | 24,298 | 102.42 | 2,488,528 |
| 2023-02-07 | Onyia Jude (Chief Scientific Officer) | Sale | 4,508 | 102.30 | 461,168 |
| 2023-02-07 | Cooke Julie (Chief Human Resources Officer) | Sale | 14,536 | 102.89 | 1,495,667 |
| 2023-02-07 | Roberts Eiry (Chief Medical Officer) | Sale | 14,424 | 102.38 | 1,476,714 |
| 2023-02-07 | Abernethy Matt (Chief Financial Officer) | Sale | 26,328 | 102.38 | 2,695,539 |
| 2023-02-07 | Benevich Eric (Chief Commercial Officer) | Sale | 17,390 | 102.36 | 1,779,953 |
| 2023-02-07 | Gano Kyle (Chief Business Development Officer) | Sale | 14,424 | 102.35 | 1,476,296 |
| 2023-02-07 | Lloyd-smith Malcolm (Chief Integration Officer) | Sale | 13,816 | 102.29 | 1,413,183 |
| 2023-02-07 | Lippoldt Darin (Chief Legal Officer) | Sale | 14,323 | 102.33 | 1,465,686 |
| 2023-02-07 | Gorman Kevin Charles (Chief Executive Officer) | Sale | 23,730 | 102.37 | 2,429,145 |
| 2023-02-06 | Boyer David W. (Chief Corp. Affairs Officer) | Sale | 240 | 105.61 | 25,346 |
| 2023-02-06 | Cooke Julie (Chief Human Resources Officer) | Sale | 1,215 | 104.87 | 127,420 |
| 2023-02-06 | Roberts Eiry (Chief Medical Officer) | Sale | 1,121 | 105.80 | 118,601 |
| 2023-02-06 | Abernethy Matt (Chief Financial Officer) | Sale | 1,280 | 105.67 | 135,253 |
| 2023-02-06 | Benevich Eric (Chief Commercial Officer) | Sale | 1,280 | 105.63 | 135,201 |
| 2023-02-06 | Gano Kyle (Chief Business Development Officer) | Sale | 1,600 | 105.64 | 169,027 |
| 2023-02-06 | Lloyd-smith Malcolm (Chief Integration Officer) | Sale | 801 | 105.81 | 84,757 |
| 2023-02-06 | Lippoldt Darin (Chief Legal Officer) | Sale | 1,041 | 105.80 | 110,141 |
| 2023-02-06 | Gorman Kevin Charles (Chief Executive Officer) | Sale | 3,040 | 105.68 | 321,258 |
| 2023-01-31 | Boyer David W. (Chief Corp. Affairs Officer) | Sale | 1,104 | 109.92 | 121,348 |
| 2023-01-31 | Onyia Jude (Chief Scientific Officer) | Sale | 126 | 108.48 | 13,668 |
| 2023-01-31 | Cooke Julie (Chief Human Resources Officer) | Sale | 916 | 108.48 | 99,367 |
| 2023-01-31 | Roberts Eiry (Chief Medical Officer) | Sale | 1,457 | 109.99 | 160,253 |
| 2023-01-31 | Abernethy Matt (Chief Financial Officer) | Sale | 1,283 | 109.98 | 141,108 |
| 2023-01-31 | Benevich Eric (Chief Commercial Officer) | Sale | 1,207 | 109.95 | 132,710 |
| 2023-01-31 | Gano Kyle (Chief Business Development Officer) | Sale | 1,541 | 109.98 | 169,486 |
| 2023-01-31 | Lloyd-smith Malcolm (Chief Integration Officer) | Sale | 1,666 | 110.02 | 183,289 |
| 2023-01-31 | Lippoldt Darin (Chief Legal Officer) | Sale | 1,250 | 109.97 | 137,463 |
| 2023-01-31 | Gorman Kevin Charles (Chief Executive Officer) | Sale | 2,707 | 110.08 | 297,997 |
| 2023-01-03 | Pops Richard F (Director) | Sale | 30,000 | 119.20 | 3,576,090 |
| 2023-01-03 | Pops Richard F (Director) | Option Ex | 30,000 | 12.71 | 381,300 |
| 2023-01-03 | Sherwin Stephen A (Director) | Sale | 60,000 | 118.86 | 7,131,480 |
| 2023-01-03 | Sherwin Stephen A (Director) | Option Ex | 60,000 | 12.85 | 770,700 |
| 2022-11-30 | Benevich Eric (Chief Commercial Officer) | Sale | 50,000 | 125.90 | 6,295,100 |
| 2022-11-30 | Benevich Eric (Chief Commercial Officer) | Option Ex | 50,000 | 40.34 | 2,016,850 |
| 2022-11-29 | Onyia Jude (Chief Scientific Officer) | Sale | 2,331 | 121.91 | 284,160 |
| 2022-11-10 | Benevich Eric (Chief Commercial Officer) | Sale | 100 | 125.36 | 12,536 |
| 2022-11-10 | Benevich Eric (Chief Commercial Officer) | Option Ex | 100 | 41.78 | 4,178 |
| 2022-11-08 | Cooke Julie (Chief Human Resources Officer) | Sale | 5,592 | 124.99 | 698,949 |
| 2022-11-08 | Cooke Julie (Chief Human Resources Officer) | Option Ex | 5,592 | 81.05 | 453,231 |
| 2022-11-08 | Benevich Eric (Chief Commercial Officer) | Sale | 24,593 | 125.33 | 3,082,314 |
| 2022-11-08 | Benevich Eric (Chief Commercial Officer) | Option Ex | 24,593 | 41.78 | 1,027,495 |
Insider trading activities including stock purchases, stock sales, and option exercises of NBIX listed in the above tables cannot be completely guaranteed as to their accuracy. For more insider trading information of Neurocrine Biosciences Inc (symbol NBIX, CIK number 914475) see the Securities and Exchange Commission (SEC) website.